ePrints

Peptide Therapeutics: Unveiling the Potential against Cancer—A Journey through 1989

Lookup NU author(s): Dr Othman AlmusaimiORCiD

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

The United States Food and Drug Administration (FDA) has approved a plethora of peptide-based drugs as effective drugs in cancer therapy. Peptides possess high specificity, permeability, target engagement, and a tolerable safety profile. They exhibit selective binding with cell surface receptors and proteins, functioning as agonists or antagonists. They also serve as imaging agents for diagnostic applications or can serve a dual-purpose as both diagnostic and therapeutic (theragnostic) agents. Therefore, they have been exploited in various forms, including linkers, peptide conjugates, and payloads. In this review, the FDA-approved prostate-specific membrane antigen (PSMA) peptide antagonists, peptide receptor radionuclide therapy (PRRT), somatostatin analogs, antibody–drug conjugates (ADCs), gonadotropin-releasing hormone (GnRH) analogs, and other peptide-based anticancer drugs are analyzed in terms of their chemical structures and properties, therapeutic targets and mechanisms of action, development journey, administration routes, and side effects.

Publication metadata

Author(s): Al Musaimi O

Publication type: Article

Publication status: Published

Journal: Cancers

Year: 2024

Volume: 16

Issue: 5

Print publication date: 02/03/2024

Online publication date: 02/03/2024

Acceptance date: 01/03/2024

Date deposited: 10/04/2024

ISSN (electronic): 2072-6694

Publisher: MDPI

URL: https://doi.org/10.3390/cancers16051032

DOI: 10.3390/cancers16051032

Data Access Statement: Not applicable.

Altmetrics

Funding

Share